{keywords}

 

The Central Institute of Hygiene and Epidemiology has allocated an additional 8 million doses of Sinopharm vaccine funded by a corporation to 25 provinces and cities nationwide.

Accordingly, in addition to 200,000 doses of vaccine provided to the sponsoring corporation and 1,500 doses for testing and sample storage, the remaining 7,798,500 doses have been distributed to 25 provinces and cities. Specifically:

11 provinces and cities in the North:

Hanoi: 1,359,000 doses; Bac Giang: 200,000 doses; Bac Ninh: 400,000 doses, Lang Son: 500,000 doses; Vinh Phuc: 100,000 doses; Yen Bai: 500,000 doses; Hai Phong: 500,000 doses; Nam Dinh: 200,000 doses; Hai Duong: 94,400 doses; Hung Yen: 147,200 doses; Quang Ninh: 700,800 doses.

5 central provinces:

Thanh Hoa: 200,000 doses; Nghe An: 200,000 doses; Quang Tri: 200,000 doses; Binh Dinh: 200,000 doses; Khanh Hoa 300,000 doses.

9 provinces and cities in the South:

HCM City: 500,000 doses; Ba Ria - Vung Tau: 100,000 doses; Long An: 200,000 doses; Lam Dong: 200,000 doses; Tay Ninh: 200,000 doses; Ben Tre: 200,000 doses; Dong Thap: 200,000 doses; Tien Giang 96,200 doses; Kien Giang 300,000 doses.

These provinces and cities are required to immediately administer the allocated Covid-19 vaccines and report on the vaccination results to the Agency of Preventive Medicine, the Central Institute of Hygiene and Epidemiology and the Institute of Hygiene and Epidemiology and Pasteur Institute.

According to statistics from the National Expanded Immunization Program, by September 18 Vietnam had administered a total of 33,555,359 doses of Covid-19 vaccines, including 27,208,264 people with one dose and 6,347,095 people with two doses.

Nguyen Lien

Nano Covax’s data for 'direct evaluation' of protective efficacy not available

Nano Covax’s data for 'direct evaluation' of protective efficacy not available

The National Ethics Committee in Biomedical Research on Sunday issued a press statement on its conclusions of a meeting one day earlier during which it looked into the mid-term phase 3 trial’s results of homegrown COVID-19 vaccine Nano Covax.